Development of inhibitors for uPAR: blocking the interaction of uPAR with its partners.
Drug Discov Today
; 26(4): 1076-1085, 2021 04.
Article
en En
| MEDLINE
| ID: mdl-33486111
ABSTRACT
Urokinase-type plasminogen activator receptor (uPAR) mediates a multitude of biological activities, has key roles in several clinical indications, including malignancies and inflammation, and, thus, has attracted intensive research over the past few decades. The pleiotropic functions of uPAR can be attributed to its interaction with an array of partners. Many inhibitors have been developed to intervene with the interaction of uPAR with these partners. Here, we review the development of these classes of uPAR inhibitor and their inhibitory mechanisms to promote the translation of these inhibitors to clinical applications.
Texto completo:
1
Colección:
01-internacional
Asunto principal:
Transducción de Señal
/
Receptores del Activador de Plasminógeno Tipo Uroquinasa
/
Descubrimiento de Drogas
Límite:
Humans
Idioma:
En
Revista:
Drug Discov Today
Asunto de la revista:
FARMACOLOGIA
/
TERAPIA POR MEDICAMENTOS
Año:
2021
Tipo del documento:
Article
País de afiliación:
China